House Publications
The Debates are the report—transcribed, edited, and corrected—of what is said in the House. The Journals are the official record of the decisions and other transactions of the House. The Order Paper and Notice Paper contains the listing of all items that may be brought forward on a particular sitting day, and notices for upcoming items.
For an advanced search, use Publication Search tool.
If you have any questions or comments regarding the accessibility of this publication, please contact us at accessible@parl.gc.ca.
|
|
|
Notice PaperNo. 319 Monday, September 17, 2018 11:00 a.m. |
|
|
|
|
Introduction of Government Bills |
|
Introduction of Private Members' Bills |
|
Notices of Motions (Routine Proceedings) |
|
Questions |
|
| Q-18862 — September 13, 2018 — Mr. Sweet (Flamborough—Glanbrook) — With regard to the Persian Gulf War, which took place between 1990 and 1991, and as of June 1, 2018: (a) how much capital has been spent by the government to commemorate the participation of the Canadian Armed Forces in the conflict; (b) which government programs have (i) received funding requests or applications to commemorate Canadian participation in the conflict, (ii) granted funding to groups or organizations seeking to commemorate that participation, (iii) rejected funding requests by a group or organization seeking to commemorate that participation; and (c) what criteria did the government use to reject the funding requests mentioned in (b)(iii)? |
| Q-18872 — September 13, 2018 — Mr. Sweet (Flamborough—Glanbrook) — With regard to the Persian Gulf War, which took place between 1990 and 1991: (a) are Canadian veterans of the Persian Gulf War eligible for Veterans Affairs Canada benefits in the same manner as all Canadian Armed Forces veterans; and (b) if the answer to (a) is negative, what are the justifications for not providing equal benefits to these veterans? |
| Q-18882 — September 13, 2018 — Mr. Davies (Vancouver Kingsway) — With regard to the Advisory Council on the Implementation of National Pharmacare (Advisory Council): (a) who will be the members of the Advisory Council, broken down by (i) nomination date, (ii) complete name, (iii) total remuneration, (iv) length of mandate; (b) on what date exactly does the government anticipate appointing the last of the initial members of the Advisory Council; (c) what are the timelines and important dates for the Advisory Council’s consultations; (d) will the Advisory Council’s consultations be held in public; (e) who will be consulted by the Advisory Council, broken down by (i) organizations or individuals already consulted, (ii) organizations or individuals to be consulted, (iii) dates of all previous and planned consultations, (iv) length of consultation period; (f) on what date exactly is the Advisory Council planning to table its interim and final reports; and (g) how will financial and human resources be allocated with respect to the Advisory Council, broken down by (i) types of expenses, (ii) allocated sums? |
| Q-18892 — September 13, 2018 — Mr. Maguire (Brandon—Souris) — With regard to the number of citizenship certificates issued to Canadians born abroad between February 15, 1977, and April 17, 1981: (a) what was the number of retention applications received from Canadians born abroad between February 15, 1977, and April 17, 1981; and (b) what was the number of applications for passports that were denied to persons born abroad between February 15, 1977, and April 17, 1981, because they would have already lost Canadian citizenship? |
| Q-18902 — September 13, 2018 — Mr. Cullen (Skeena—Bulkley Valley) — With regard to the impending purchase of the Trans Mountain pipeline by the government, can the Minister of Natural Resources confirm in relation to the Pipeline Safety Act and National Energy Board Act: (a) whether the government considers itself a company as authorized under these acts to operate a pipeline; and (b) if the answer to (a) is affirmative, how this pertains to the National Energy Board’s mandate under these acts to order a company to reimburse the costs incurred by any government institution due to the unintended or uncontrolled release of oil, gas or any other commodity from a pipeline? |
| Q-18912 — September 13, 2018 — Mr. Cullen (Skeena—Bulkley Valley) — With regard to consultations undertaken by Kinder Morgan with Indigenous groups impacted by the Trans Mountain pipeline expansion and given the impending purchase of the pipeline by the government, will the Minister of Natural Resources: (a) table all mutual benefit agreements previously reached between Kinder Morgan and First Nation band councils given that they will soon constitute agreements reached with the Crown; and (b) guarantee that all such agreements established the free, prior and informed consent to the pipeline from each band? |
| Q-18922 — September 13, 2018 — Ms. Brosseau (Berthier—Maskinongé) — With regard to federal spending in the riding of Berthier—Maskinongé, for each fiscal year since 2014, inclusively: what are the details of all grants and contributions and all loans to every organization, group, business or municipality, broken down by the (i) name of the recipient, (ii) municipality of the recipient, (iii) date on which the funding was received, (iv) amount received, (v) department or agency that provided the funding, (vi) program under which the grant, contribution or loan was made, (vii) nature or purpose? |
| Q-18932 — September 13, 2018 — Ms. Duncan (Edmonton Strathcona) — With regard to Health Canada’s notice of a recall for a list of Valsartan products supplied by Chinese corporation Zhejiang Huahai Pharmaceuticals: (a) on what date did Health Canada become aware of the contamination of these drugs with N-nitrosodimethylamine (NDMA); (b) was the recall issued at the request of Canadian authorities; (c) what is deemed a long-term exposure to this carcinogen; (d) if there was a delay in issuing the recall after Health Canada was informed of the contamination, what were the reasons for the delay in the public notice; (e) how was Health Canada made aware of the contamination of the valsartan medicines; (f) did Health Canada directly conduct any laboratory tests on these drugs to determine their safety before approving their use in Canada; (g) has Health Canada or any federal authority undertaken any investigations of the laboratory and manufacturing facilities of Zhejiang Huahai Pharmaceuticals; (h) why did Health Canada advise patients to continue taking the Valsartan products despite the knowledge it was contaminated with a carcinogen and who made that decision; (i) are any other products manufactured by Zhejiang Huahai Pharmaceuticals currently being distributed, sold or prescribed in Canada; (j) what actions has Health Canada taken to test alternative blood pressure medicines being prescribed in Canada to determine their safety; and (k) what information has been provided to Health Canada on adverse effects reported by Canadians taking Valsartan? |
| Q-18942 — September 13, 2018 — Mr. Kmiec (Calgary Shepard) — With regard to the National Joint Council’s Relocation Directive, which reimburses federal employees when relocating for work, for the calendar years 2016, 2017 and 2018: (a) how many employees, agents, or contractors of the federal government made claims for relocation funding each year, broken down by government department or agency; (b) how many employees, agents, or contractors of the federal government were provided with reimbursement for relocation each year, broken down by government department or agency; (c) in the instances where relocation funding was provided, how many instances arose from employer-requested relocation in each year; (d) in the instances where relocation funding was provided, how many instances arose from employee-requested relocation in each year; (e) what was the annual aggregate amount in Canadian dollars spent by each government agency or department in remitting relocation funding, broken down by the benefit categories outlined in appendix B of the National Joint Council’s Relocation Directive; (f) which employees, agents, or contractors of the federal government received relocation funding in each year, itemized to include their agency or department, their job title, the amount of relocation funding remitted, broken down by the benefit categories outlined in appendix B of the National Joint Council’s Relocation Directive, and where the individual was relocated from and to; (g) what is the aggregate amount of funding, across all government departments and agencies, remitted in each year under the Relocation Directive’s benefit categories that pertain to real estate commission and realtor fees; (h) what is the aggregate amount of funding, across all government departments and agencies, remitted in each year under the Relocation Directive’s benefit categories that pertain to home equity loss; and (i) what is the aggregate amount of funding, across all government departments and agencies, remitted in each year under the Relocation Directive’s benefit categories that pertain to mortgages, mortgage default insurance, and mortgage paydown penalties? |
Notices of Motions for the Production of Papers |
|
Business of Supply |
|
Government Business |
|
Private Members' Notices of Motions |
|
| M-198 — September 13, 2018 — Mr. Julian (New Westminster—Burnaby) — That, in the opinion of the House, the government should: (a) recognize that health care is a basic human right and that no Canadian should be denied access to the prescription medicine they need to be healthy; (b) recognize that a “medical cannabis product” is a cannabis product sold for medical purposes pursuant to a license for the sale of cannabis for medical purposes granted in accordance with the Controlled Drugs and Substances Act or the Cannabis Act; (c) recognize that although medical cannabis does not have a Drug Identification Number, it is produced and sold in a highly regulated regime known as the Access to Cannabis for Medical Purposes Regulations; (d) recognize that patients who are legally authorized or prescribed cannabis for medical purposes by a physician and prescribing healthcare practitioner can legally purchase quality-controlled cannabis for medical purposes from a Health Canada licensed producer; (e) recognize that the Canada Revenue Agency considers cannabis for medical purposes a tax-deductible medical expense; (f) allow for reasonable access to medical cannabis for all Canadians who have been authorized to use it by a health care practitioner; (g) recognize that medical cannabis patients, including pediatric patients, already pay sales tax and shipping costs on medical cannabis and are not eligible for reimbursement under most insurance plans in Canada; (h) recognize that its proposal to apply excise taxes to medical cannabis, in addition to the existing sales tax, will disadvantage over 260,000 Canadians and their families; (i) not apply an excise duty to cannabis sold for medical purposes; (j) recognize that medical cannabis should be exempt from the federal Goods and Services Tax; (k) exempt medical cannabis from any taxes including the new excise tax after the passage of Bill C-74, Budget Implementation Act, 2018, No. 1; and (l) zero-rate the medical cannabis tax in line with all other prescription medicine and exempt medical cannabis from any additional taxes by amending T 3 Amendments to the Excise Act, 2001 (Cannabis Taxation), the Excise Tax Act and Other Related Texts, 69(4) Section 2 of the Act, in order to allow for reasonable access to medical cannabis for all Canadians authorized to use it by a health care practitioner. |
Private Members' Business |
| S-228 — June 6, 2018 — Mr. Eyolfson (Charleswood—St. James—Assiniboia—Headingley) — Third reading of Bill S-228, An Act to amend the Food and Drugs Act (prohibiting food and beverage marketing directed at children). |
| Pursuant to Standing Order 86(3), jointly seconded by: |
| Ms. Sidhu (Brampton South) — October 23, 2017 |
| Mr. McKinnon (Coquitlam—Port Coquitlam) — October 26, 2017 |
| Debate — 1 hour remaining, pursuant to Standing Order 98(2). |
| Voting — at the expiry of the time provided for debate, pursuant to Standing Order 98(4). |
|
|
|
| 2 Response requested within 45 days |
|